Mulmit

Surrozen, Inc./DESurrozen, Inc./DE

SRZN Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2025-12-313,477,000-42,092,000-242,026,000-32.37
2024-12-3110,655,000-25,539,000-63,564,000-21.67
2023-12-310-45,780,000-43,042,000-21.33
2022-12-3112,500,000-44,339,000-36,004,000-15.56
2021-12-310-54,391,000-54,648,000-2.21

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-07-22TCG Crossover GP II, LLC162,500
2026-07-22TCG Crossover GP II, LLC162,500
2026-06-15Maleki Andrew PedrumChief Financial Officer607
2026-06-15Li YangExec. Vice President, Research1,666
2026-06-15Williams Charles OChief Operating Officer1,666
2026-06-15Parker Craig CChief Executive Officer1,622
2026-05-13Kutzkey Tim5,550
2026-05-13Rothenberg Mace5,550
2026-05-13WOODHOUSE DAVID J5,550
2026-05-13Haak-Frendscho Mary5,550
2026-05-13CHAI CHRISTOPHER Y5,550
2026-05-13BJERKHOLT ERIC5,550

8-K events

FiledItems
2026-08-06Results of operations
2026-05-14Submission of matters to a vote
2026-05-06Results of operations · Financial statements and exhibits
2026-03-23Results of operations · Financial statements and exhibits
2026-01-30Officer or director change
2025-11-07Results of operations · Officer or director change
2025-10-17Termination of a material agreement
2025-08-29Entry into a material agreement · Financial statements and exhibits
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

Biological Products, (No Diagnostic Substances) — 같은 업종, 그리고 규모가 비슷한 기업Biological Products, (No Diagnostic Substances) — and other companies of a similar size

SEC가 같은 업종(Biological Products, (No Diagnostic Substances))으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (Biological Products, (No Diagnostic Substances)) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.